LIVN:NSD-LivaNova PLC (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 51.07

Change

+0.07 (+0.14)%

Market Cap

USD 2.64B

Volume

0.57M

Analyst Target

USD 65.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

+0.52 (+0.75%)

USD 27.85B
PODD Insulet Corporation

+0.57 (+0.24%)

USD 16.40B
BRKR Bruker Corporation

+1.77 (+2.72%)

USD 9.94B
MASI Masimo Corporation

-0.70 (-0.61%)

USD 6.03B
TMDX TransMedics Group Inc

-0.12 (-0.08%)

USD 5.04B
PRCT Procept Biorobotics Corp

+3.16 (+3.96%)

USD 4.00B
AXNX Axonics Modulation Technologie..

-0.18 (-0.26%)

USD 3.52B
QDEL Quidel Corporation

-0.12 (-0.26%)

USD 3.06B
TNDM Tandem Diabetes Care Inc

-0.42 (-0.98%)

USD 2.88B
NARI Inari Medical Inc

+0.28 (+0.63%)

USD 2.61B

ETFs Containing LIVN

W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.05 (-0.39%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.01 (-0.39%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.01 (-0.39%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.03 (-0.39%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.29% 69% C- 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.29% 69% C- 45% F
Trailing 12 Months  
Capital Gain -10.56% 61% D- 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.56% 61% D- 37% F
Trailing 5 Years  
Capital Gain -34.97% 57% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.97% 57% F 30% F
Average Annual (5 Year Horizon)  
Capital Gain 2.36% 53% F 49% F
Dividend Return 2.36% 53% F 45% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 36.86% 74% C 51% F
Risk Adjusted Return 6.40% 60% D- 44% F
Market Capitalization 2.64B 92% A 82% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector